Helix BioPharma Partners with ProMab on CAR-T Therapies
The collaboration between the two companies aims to finish all necessary work needed to file for a first-in-human study by early 2019.
Helix BioPharma, an immuno-oncology company, has signed a collaboration agreement with ProMab Biotechnologies to develop novel antibody and chimeric antigen receptor T-cell (CAR-T) therapy for particular hematological malignancies, such as multiple myeloma, the company announced in a March 21, 2018 press release.
Helix had previously announced the signing of a binding letter of intent with ProMab to develop CAR-T for various hematological malignancies and solid tumors. The company has now signed its first scientific collaboration to co-develop a cell-based therapy for multiple myeloma (MM).
The MM co-development program will aim to complete all necessary work and intends to file for a first-in-human study by early 2019. Under the agreement, Helix will retain commercial rights for this CAR-T product in Canada and Europe and is currently in the process of reviewing the expansion criteria required for its European operations in Poland to facilitate commercialization.
Source: Helix BioPharma
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
